GLPwatch
Papers (12034)
Page 191 of 201, ranked by citation count.
- [Glucagon-like peptide-1 agonists and heart failure].
- [Possibilities of therapy GLP1 RA for diabetics with nephropathy].
- Orforglipron Calcium.
- Association of semaglutide use with outcomes in chronic plantar heel pain: a prospective observational cohort and a pilot interventional study.
- Once-Weekly Semaglutide in Adolescents with Obesity.
- The Neuroprotective Potentials of Dual GIP/GLP1-RA (Tirzepatide): From Preclinical Experiments to Clinical Trials: A Scoping Review.
- Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5.
- An alternative combination therapy for type 2 diabetes?
- Phyllanthus niruri niosomes ameliorate obesity-induced hepatic steatosis in rats via modulating MALAT1/miR-206/GLP-1R signaling and hepatic lipid metabolism.
- Comparative Efficacy of Semaglutide versus Liraglutide on Weight Loss and Glycaemic Control.
- Ischemic Colitis Associated With Tirzepatide Therapy in a Young Female Patient: A Case Report.
- RETRACTION: Comparative efficacy of semaglutide versus liraglutide on weight loss and glycaemic control.
- Semaglutide and tirzepatide: Oral cavity effects of weight-loss therapies.
- Multi-target-directed drugs: new additions in 2025 and post-marketing safety surveillance of drugs marketed in 2022-2024.
- Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.
- Paradigm Shifts to Improve Treatment in Youth with Type 2 Diabetes.
- In adults with obesity but without type 2 diabetes, tirzepatide increased weight loss at 72 wk compared with semaglutide.
- The future use of liraglutide: implications of the LEAD-2 study for treatment guidelines in type 2 diabetes.
- Efficacy and safety of pharmacological and non-pharmacological interventions for antipsychotic-induced weight gain in individuals with schizophrenia: A systematic review and network meta-analysis of 55 clinical trials.
- Baseline metabolite profiles predict the glucose-lowering efficacy of exenatide in patients with type 2 diabetes.
- In response: Considerations regarding compounding pharmacies and GLP-1 agonists.
- Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment [Letter].
- Cardiometabolic Effects of Semaglutide in Individuals with Type 2 Diabetes in the United Arab Emirates: Real-World 12-Month Outcomes and Predictors of Response.
- Correction to "Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus".
- NEJM at AHA - Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- NewDrugs 2017, part 2.
- Anti-Obesity Medications in Longevity and Aesthetic Medicine.
- Lax oversight of semaglutide advertising could harm patients, warn critics.
- Evaluating The Long-Term Cost-Effectiveness Of Liraglutide 1.2 Mg And Exenatide In Patients With Type 2 Diabetes Mellitus.
- Dulaglutide-Associated Lichen Planus Pemphigoides.
- Preoperative GLP-1 Receptor Agonist Use and Postoperative Outcomes in Orthopaedic Surgery: A Scoping Review of Perioperative and Recovery Outcomes.
- Liraglutide Effect on Weight and A1C in Patients with Type 2 Diabetes Mellitus: Real-World Data from a Single Tertiary Care Center in Saudi Arabia.
- Estimating treatment effects in clinical studies of Alzheimer's disease: What are estimands and why do we need them?
- New Injectable Drug for Type 2 Diabetes.
- Highlights of Cardiovascular Disease Prevention Studies Presented at the 2026 American College of Cardiology Conference.
- Beyond Patient Factors: Are we Missing the Surgical Context in Comparing Tirzepatide and Semaglutide Post-CABG?
- Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin or Exenatide in Patients With Inadequately Controlled Type 2 Diabetes On Oral Antidiabetic Drugs In Greece.
- Weight Loss, Adverse Effects With GLP-1 Medications May Be Influenced by Genetics.
- Interpreting Post-Discontinuation Trajectories After Semaglutide or Tirzepatide.
- [Basal insulin and GLP-1 agonist potentiate each other (interview by Dr. med Dirk Einecke)].
- Comment on 'Semaglutide and Tirzepatide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World (STEER)'.
- Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials.
- Cardiovascular benefits of liraglutide in patients with type 2 diabetes: an in-depth exploration.
- ICER report demonstrates both the value and challenges in financing of weight loss medications.
- Semaglutide versus caloric restriction-induced weight loss: insights into effects on skeletal muscle mass and function.
- Correction.
- Impact of Fibrotic Metabolic Dysfunction-Associated Steatohepatitis as a New Indication on Semaglutide Eligibility in the US Adult Population.
- Liraglutide Causing Pancreatitis in an Indian Obese Female: A Case Report and Review of the Literature.
- Efficacy and Safety of Oral Semaglutide in the Management of Diabetes and Obesity: A Comprehensive Meta-analysis of Real-world Evidence.
- Acute onset of neovascular age-related macular degeneration after initiation of tirzepatide.
- Effects of the glucagon-like peptide-1 receptor agonist liraglutide on retinal endothelial function and oxidative stress during sepsis.
- Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
- Tirzepatide as an Add-on for Participants with Inadequate Glycemic Control Using Basal Insulin: Pooled Subgroup Analysis of SURPASS-5 and -6.
- Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review.
- Cost-effectiveness and budget-impact analysis of tirzepatide in heart failure with preserved ejection fraction and obesity in the German health-care system.
- Glucagon-Like Peptide-1 Receptor Agonist and Hyponatremia: A Potential Association.
- Ameliorative effect of lixisenatide on diabetic cardiovascular damage and its enhancement via ticagrelor co-administration in rats: possible role of eNOS and NrF₂ /HO-1 signaling.
- Semaglutide and Cardiovascular Outcomes.
- Vicarious efficacy of tirzepatide in a cohabiting couple: An observational case report.
- Metabolic miracle or misguided shift? Tirzepatide in the era of obstructive sleep apnea (OSA).